InvestorsHub Logo
Followers 260
Posts 18196
Boards Moderated 0
Alias Born 01/19/2006

Re: None

Thursday, 05/10/2018 3:42:09 PM

Thursday, May 10, 2018 3:42:09 PM

Post# of 1850
DOJ on behalf of FDA seeks injunction against use of certain stem cells by certain companies; details here:

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm607257.htm

"The U.S. Food and Drug Administration, in two complaints filed today in federal court(May 9), is seeking permanent injunctions to stop two stem cell clinics from marketing stem cell products without FDA approval and for significant deviations from current good manufacturing practice requirements.

“Cell-based regenerative medicine holds significant medical opportunity, but we’ve also seen some bad actors leverage the scientific promise of this field to peddle unapproved treatments that put patients’ health at risk. In some instances, patients have suffered serious and permanent harm after receiving these unapproved products. In the two cases filed today, the clinics and their leadership have continued to disregard the law and more importantly, patient safety. We cannot allow unproven products that exploit the hope of patients and their loved ones,” said FDA Commissioner Scott Gottlieb, M.D. “We support sound, scientific research and regulation of cell-based regenerative medicine, and the FDA has advanced a comprehensive policy framework to promote the approval of regenerative medicine products. But at the same time, the FDA will continue to take enforcement actions against clinics that abuse the trust of patients and endanger their health with inadequate manufacturing conditions or by purporting to have treatments that are being manufactured and used in ways that make them drugs under the existing law but have not been proven safe or effective for any use.....”[more]
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.